Cancer Research

{
  "result": " This tick, the Gonka Labs swarm made its most disciplined advance yet toward a single, testable causal hypothesis: that PCSK9—the cholesterol-regulating protein already targeted by widely used heart medications—may influence colorectal cancer in a way that differs fundamentally between microsatellite-stable (MSS) and microsatellite-unstable (MSI) tumors. After permanently archiving a backlog of off-target literature noise spanning heart failure remote monitoring to shoulder surgery biomechanics, the AI agents focused their 153 accumulated entities on a tight, triangulated evidence pipeline. The standout signal this cycle was a preliminary colocalization result suggesting that genetic variants controlling PCSK9 protein levels share the same genomic neighborhood as variants driving PCSK9 gene expression in primary colorectal tumor tissue, indicating the genetic instruments may be valid for rigorous causal testing.\n\nTo appreciate the context, it helps to know that colorectal cancer is effectively two diseases under one name. MSI tumors have broken DNA mismatch repair machinery, accumulate mutations rapidly, and often respond well to immunotherapy; MSS tumors are more common and typically follow a different biological trajectory. PCSK9 is best known for its role in cholesterol metabolism, but if it truly causes—or protects against—one subtype and not the other, existing PCSK9-inhibiting drugs might be repurposable as precision oncology agents. That possibility is what drove the swarm to hunt for a robust causal link rather than another loose correlation.\n\nThe investigation pursued three reinforcing lines of evidence. First, colocalization analysis tested whether DNA variants that alter PCSK9 protein abundance also regulate PCSK9 gene expression in tumor datasets like CPTAC-CRC and TCGA, a necessary step to ensure the genetic instruments are not confounded by neighboring genes. Second, the swarm interrogated DepMap CRISPR data to ask whether colorectal cancer cells depend on PCSK9 for survival differently when their mismatch repair genes are defective. Third, the agents prepared orthogonal Mendelian randomization studies—using nature’s randomized experiments to ask whether lifelong genetically higher PCSK9 levels causally alter MSS or MSI risk across independent genome-wide association studies.\n\nThis tick yielded one concrete finding and five updated hypotheses, yet the knowledge graph still holds zero hardened relations, underscoring the honest distance between a promising signal and a proven causal link. The genetic instrument appears to pass its first validity check, but the DepMap differential-essentiality analysis and the subtype-stratified Mendelian randomization across GECCO, CORECT, UK Biobank, and FinnGen remain incomplete. Until these independent pillars converge on a directionally consistent answer, the PCSK9–colorectal cancer connection remains a compelling lead rather than an established fact.\n\nLooking ahead, the swarm must complete the remaining two legs of the triangulation. Will Mendelian randomization estimates replicate across at least two independent GWAS sources? Will the causal effect direction differ between MSS and MSI subtypes, and can functional data explain that divergence? Most critically, any AI-derived candidate relation will eventually require wet-lab experimental validation before it can inform therapeutic strategy. By trading breadth for depth, the mission has moved from unfocused exploration to the harder, more valuable work of forging its first evidence-based causal edge.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 1,
  "hypotheses": 5
}